This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals Announces Additional Results From Lymphoseek® Phase 3 Clinical Trial In Head And Neck Cancer At American College Of Surgeons 2013 Annual Clinical Congress

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the presentation of additional results from its pivotal Phase 3 clinical trial (NEO3-06) for Lymphoseek ® (technetium Tc 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma. Navidea previously announced that the NEO3-06 study met the primary false negative rate efficacy endpoint of accurately identifying sentinel lymph nodes (SLNs) in subjects with squamous cell carcinoma of the head or in the mouth, as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck. This surgery is considered the “gold standard” to determine the presence and extent of cancer spread in lymph nodes of patients with head and neck squamous cell carcinoma. The now completed full study report indicates that Lymphoseek also met all other pre-specified study endpoints, including sensitivity, negative predictive value and overall accuracy relative to the pathology status of non-SLNs. No differences were observed in the ability of Lymphoseek to detect SLNs between same-day or subsequent-day surgery following Lymphoseek injection. Lymphoseek is a novel, receptor-targeted, small-molecule radiopharmaceutical approved by the U.S. Food and Drug Administration for use in lymphatic mapping to assist in the localization of lymph nodes draining primary tumor in patients with breast cancer or melanoma. The results were presented at the American College of Surgeons 2013 Annual Clinical Congress by Amit Agrawal, MD, Associate Professor, The Ohio State University College of Medicine, Department of Otolaryngology – Head and Neck Surgery, a lead investigator on the NEO3-06 Phase 3 clinical trial.

“Thousands of patients with head and neck cancer stand to benefit from accurate diagnostic evaluation of their condition, and we are pleased that the final results for Lymphoseek from our NEO3-06 Phase 3 clinical trial are being presented to surgeons attending the prestigious American College of Surgeons Clinical Congress,” said Mark Pykett, VMD, PhD, Chief Executive Officer of Navidea. “The NEO3-06 trial is representative of Navidea’s global strategy to expand Lymphoseek utilization into multiple cancer types with the aim of assisting physicians in improving accuracy and evaluating the extent of disease. As previously announced, we closed the NEO3-06 trial at the recommendation of the Data Safety Monitoring Committee. Based on study results and data analysis and dialogue with the U.S. Food and Drug Administration (FDA), we are working to file an sNDA for Lymphoseek with the FDA by the end of this year and anticipate EMA action related to the EU MAA for Lymphoseek also by year end.”

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%
YHOO $36.61 0.06%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs